Last update 01 Nov 2024

Atypical Squamous Cells of the Cervix

Last update 01 Nov 2024

Basic Info

Synonyms

ASC Atypical Squamous Cells, ASC H Atypical Squamous Cells, Cannot Rule Out High Grade Squamous Intra epithelial Lesion, ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-epithelial Lesion

+ [25]

Introduction

Morphological abnormalities of the cervical EPITHELIUM, usually revealed in PAP SMEAR, which do not meet the criteria for squamous CERVICAL INTRAEPITHELIAL NEOPLASIA or SQUAMOUS CELL CARCINOMAS of the CERVIX . It may be a sign of infection with certain types of human papillomavirus (HPV).or sign of a benign (not cancer) growth, such as a cyst or polyp or, in menopausal women, of low hormone levels. More testing, such as HPV test, may be needed.

Drugs associated with Atypical Squamous Cells of the Cervix

FluBHPVE6E7

Target

HPV E6 x HPV E7

Mechanism

E7 inhibitors [+1]

Active Org.

BlueSky Immunotherapies GmbH

Originator Org.-

Active Indication

HPV positive oropharyngeal squamous cell carcinoma [+5]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

pNGVL4aCRTE6E7L2

Target-

Mechanism

Immunostimulants

Active Org.

The Johns Hopkins University [+2]

Originator Org.

The University of Alabama at Birmingham

Active Indication

Atypical Squamous Cells of the Cervix [+2]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

GTL-001

Target-

Mechanism

CD4-positive T-lymphocytes stimulants [+1]

Active Org.-

Originator Org.

Genticel SA

Active Indication-

Inactive Indication

Atypical Squamous Cells of the Cervix [+4]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Atypical Squamous Cells of the Cervix

NCT05829629 / RecruitingPhase 1

Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women With NILM, ASC-US, LSIL or Low-grade CIN

BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).

Start Date12 Sep 2023

Sponsor / Collaborator

BlueSky Immunotherapies GmbH

NCT03913117 / RecruitingPhase 1IIT

Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular pNGVL4aCRTE6E7L2 and TA-CIN Administration for the Treatment of Patients With Persistent HPV16+ ASC-US or LSIL

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

Start Date10 Jul 2023

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT05613283 / Active, not recruitingNot ApplicableIIT

Primary Cervical Cancer Screening by Self-sampling HPV Test

Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider, which is labor consuming and the coverage and compliance are both relatively low in some areas. Non-invasive hrHPV self-sampling test appears to be more acceptable and may improve the HPV screening coverage. This study aims to evaluate the clinical performance of a newly developed urine/vaginal self-sampling hrHPV test in Cervical cancer screening.

Start Date19 Nov 2022

Sponsor / Collaborator

Peking University People's Hospital

100 Clinical Results associated with Atypical Squamous Cells of the Cervix

100 Translational Medicine associated with Atypical Squamous Cells of the Cervix

0 Patents (Medical) associated with Atypical Squamous Cells of the Cervix

1,225

Literatures (Medical) associated with Atypical Squamous Cells of the Cervix

01 Dec 2024·European Journal of Radiology

Does ultrasound guidance decrease femoral access site complications in neurointerventional procedures? A retrospective cohort study

Article

Author: Miyake, Shigeta ; Falzon, Andrew ; Phei Kee, Tze ; Maganti, Manjula ; Chung, Emily M ; Ghazimoghadam, Saba ; Krings, Timo

BACKGROUNDUltrasound has been increasingly used to guide femoral arterial access for neuroendovascular procedures. Its effect on the safety outcomes has yet to be established.PURPOSEThe purpose is to determine the effect of ultrasound-guided punctures on femoral access site complications (ASC), and to identify other potential predictors of ASC.MATERIALS AND METHODSWe conducted a retrospective analysis of all the neurovascular cases performed with femoral arterial access between Jan 2016 and Dec 2022. Two groups of patients were selected: the first group had femoral arterial puncture without ultrasound guidance between Jan 2016 and Dec 2017 while the second group received femoral arterial puncture with ultrasound guidance between July 2019 and Dec 2022. Univariable and multivariable logistic regression analysis was conducted.RESULTSA total of 2347 patients and 3181 procedures were included - 1376 in the non-ultrasound group and 1805 in the ultrasound group. The complication rate of femoral arterial access was 2 % (58/3181). There was no statistically significant difference in complication rate between the ultrasound and the non-ultrasound groups (p-value 0.821). Interventional procedures (in particular EVT), larger sheath size use (>/=7Fr) and DAPT were shown to be the independent predictors of femoral arterial ASC (p-value < 0.001), in both univariable and multivariable analyses. The use of larger sheath size and EVT procedures have lower odds of having complications in the ultrasound group compared to the non-ultrasound group (OR: 0.42 (0.09-1.83); p = 0.249 and OR: 0.64 (0.09-4.59); p = 0.663, respectively).CONCLUSIONOur study found that the use of ultrasound does not have statistically significant impact on the safety outcome of femoral arterial access in neuro-endovascular procedures. It is, however, of benefit in high-risk cases. Independent predictors of femoral ASC include interventional vs diagnostic procedures, larger sheath size and DAPT intake. In these high-risk cases, ultrasound guidance helps to minimize femoral ASC.

01 Sep 2024·Diagnostic Cytopathology

Evaluation of dual p16/Ki‐67 immunostaining on anal cytology specimens

Article

Author: Gonzalez, Abel A ; Smithgall, Marie C ; Towne, William S ; Cimic, Adela

AbstractIntroductionDual immunostaining for p16/Ki67 is FDA‐approved for use on liquid‐based cervical cytology specimens; however, the utility of dual staining in anal cytology especially for ASCUS risk stratification is not well established.MethodsWe investigated dual staining performance on anal cytology specimens and correlated with subsequent cytologic interpretation, high‐risk HPV status, and anal biopsy results. Dual staining for p16/Ki‐67 was performed on all liquid‐based anal cytology specimens from December 2021 to June 2022 (n = 43).ResultsThree patients had high grade squamous intraepithelial lesion (HSIL/AIN2‐3) on biopsy; dual staining was positive in all three cases. All HR‐HPV negative cases were negative for dual staining. Among the 12 ASCUS samples with subsequent anal biopsy results all also had HR‐HPV testing. Due to small sample size of cases with squamous intraepithelial lesion (SIL) diagnosed on biopsy, the sensitivity and positive predictive value was not calculated. However, the specificity and negative predictive value of p16/Ki‐67 dual staining for SIL of any grade on biopsy were 1 (95% CI: 0.66–1) and 0.9 (95% CI: 0.65–0.97) respectively, whereas the specificity and negative predictive value of HR‐HPV testing for SIL of any grade on biopsy were 0.44 (95% CI: 0.14–0.79) and 0.8 (95% CI: 0.41–0.96) respectively.ConclusionDual p16/Ki‐67 staining indicates transforming HPV infection and could help serve as an ancillary test for risk stratification for atypical anal cytology specimens. Among ASCUS samples, dual staining was specific for SIL of any grade with a high negative predictive value and therefore could be useful in clinical practices with limited availability for follow‐up care.

01 Aug 2024·The Journal of Obstetrics and Gynecology of India

“Modernizing Cervical Cytology Screening with Liquid-Based Methods at Community-Level Hospitals: A Much-Needed Breakthrough for India”

Article

Author: Balsarkar, Geetha ; Tambvekar, Sunil E. ; Tambvekar, Sunil E

IntroductionCervical cancer still ranks highest causing cancer-related morbidity and mortality in women in India. It is prudent to emphasise and implement cervical cancer screening strategies in the population efficiently and with regular intervals. Conventionally, PAP smear cytology is obtained by wooden spatula-Ayre's spatula. To improve sensitivity and specificity of the procedure and detection rate, better techniques of cells retrieval are available mainly liquid-based cytology (LBC), with help of cyto-brush. Literature has consistently proven efficiency of the technique and also reduced the proportion of inadequate sampling. We conduct this study to compare both the techniques and efficiency in a community hospital from data over 6 years, to asses its role and benefits among Indian women.Aims and ObjectivesTo compare conventional PAP smear and liquid-based cytology techniques analysing detection rates of positive lesions (CIN and also includes ASCUS and malignant), incidence of inadequate sampling, efficiency and cost-effectiveness.MethodsThis is retrospective study at tertiary care obstetric hospital affiliated to government-run medical college in a metropolitan city of Mumbai. Data are retrieved from the Pathology Department, Medical Records Department, laboratory books and OPD registers. Pap's smear sampling was done mainly from OPD with all indications including routine tests as a part of gynaecological evaluation and screening, as well as for suspicious lesions on inspection. Group A consists women who had conventional PAP smear test for 3 years (Dec 2015-Nov 2018) and Group B had women who benefited by LBC method for 3 years (Dec 2018-Nov 2021). COVID-19 pandemic majorly affected the routine gynaecological OPD practice during 2021 as hospital was COVID facility hospital.ResultsDemographic parameters and presentations were comparable and similar. LBC methods have higher detection rate for positive reports, including ASCUS. But results were comparable in both groups and not statistically different. Importantly, incidences of inadequate sampling are reduced significantly with the LBC method. Unsatisfactory smears war high in Group A (7.752%) compared to Group B (3.712%) p-value 0.005, stating the increased rate of requirement of sending repeat smears, which involves higher engagement of time, resources and active participation from healthcare personnel.ConclusionGood detection rates and significantly low rates of unsatisfactory smears make LBC rational and cost-effective. These are the times to switch to liquid-based cytology techniques, especially at the community level hospitals; in order to detect more women with cervical premalignant as well as malignant neoplastic lesions and to save lives. This can be made possible by emphasising the policy makers to incorporate these services through quality resources.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Atypical Squamous Cells of the Cervix

Basic Info

Related

Analysis